BioMS Medical expands pivotal multiple sclerosis trial into The Netherlands

Toronto Stock Exchange Symbol: MS

EDMONTON, 

 BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced it has
received approval to start patient enrolment in The Netherlands for its
pivotal phase II/III clinical trial of MBP8298, a proprietary synthetic
peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
Approval was received from the Competent Authority in The Netherlands, CCMO
(Central Committee on Research Involving Human Subjects).

Pivotal Phase II/III Multiple Sclerosis Trial
BioMS Medical is currently enrolling patients across Canada, the U.K.,
Sweden and Denmark in its pivotal phase II/III clinical trial evaluating
MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS).
The trial is a randomized, double-blind study enrolling approximately 553
patients who will be administered either MBP8298 or placebo intravenously
every six months for a period of two years. The primary clinical endpoint for
the trial is defined as a statistically and clinically significant increase in
the time to progression of the disease as measured by the Expanded Disability
Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response
genes. Time to disease progression in patients with other HLA-DR types will be
assessed separately as an exploratory arm of the same study. To date the trial
has successfully passed four safety reviews by its independent Data Safety
Monitoring Board.

About BioMS Medical Corp.
-------------------------
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298, is for the treatment of multiple sclerosis and is
currently in a pivotal phase II/III clinical trial across Canada and Europe.
For further information please visit our website at www.biomsmedical.com.

This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of BioMS Medical with respect to
its performance, business and future events. Such statements are subject to a
number of risks, uncertainties and assumptions. Actual results and events may
vary significantly.



For further information: Tony Hesby, Ryan Giese, Corporate
Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax,
E-mail: rgiese@biomsmedical.com, Internet: www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail:
jsmith@equicomgroup.com; Mr. Barry Mire, Investor Relations, Phone: (514)
939-3989, E-mail: bmire@renmarkfinancial.com